<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039908</url>
  </required_header>
  <id_info>
    <org_study_id>MH099030</org_study_id>
    <nct_id>NCT02039908</nct_id>
  </id_info>
  <brief_title>Examining Tolerance to CNS Stimulants in ADHD</brief_title>
  <official_title>Examining Tolerance to CNS Stimulants in ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida International University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although stimulant medication is a well-established treatment for ADHD, it is often necessary
      for doctors to increase the dose over time to maintain the benefits of the medication. While
      medication can be very effective for improving symptoms of ADHD during the first year of use,
      it has not been found to significantly improve the long term course of children with ADHD.
      For example, in large research studies, groups of children who take medication for ten years
      do not have consistently better academic grades than groups of children who never used
      medication (individual results will vary from child to child).

      In order to help children with ADHD achieve the best possible outcomes, it is important for
      doctors to study why this happens. One possible reason is development of tolerance to the
      medication. Tolerance means that a drug's effects decrease when it is taken consistently over
      time, so that an increased dose is needed to continue showing effects. Some doctors believe
      that children who take stimulant medication for ADHD develop tolerance to it which would
      explain why benefits may not persist over time, but no research studies have been done to
      measure whether this occurs. This study aims to see if children show a tolerance effect to
      stimulant medication and whether that tolerance can be prevented by taking short breaks from
      the medication called medication holidays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an innovative evaluation of tolerance using an objective measure in an analog
      classroom. Each subject will complete the a 10-minute math test twice a day for three weeks
      on optimal dose or placebo, and then be crossed over to the other condition. Within-subject
      drug/placebo differences will be compared over the three weeks of exposure to assess
      tolerance in the analog setting.

      When school commences, 50% of the sample will be randomized to 7-day-a-week (continuous)
      dosing and 50% to 5-day-a- week (weekend holidays) dosing to examine the efficacy of
      prescribed weekend drug holidays for combatting need for dose escalations (tolerance) during
      the school year.

      Participants will be assessed monthly to detect deteriorating functioning. Using a
      standardized protocol, study physicians will increase dose for subjects in either arm who
      meet defined impairment thresholds. The difference between the two dosing conditions will
      inform regarding how best to deal with tolerance in clinical application.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Changes Required Per Protocol</measure>
    <time_frame>10 months</time_frame>
    <description>Monthly evaluations of medication efficacy will be used to determine whether dose adjustments are needed due to anticipated tolerance effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Increase</measure>
    <time_frame>10 months</time_frame>
    <description>The amount of time elapsed before a child requires a dose increase during the school year will be measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medication Dose</measure>
    <time_frame>End of Phase 2 School Year</time_frame>
    <description>Dose of medication reported in mg/kg/day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Attention-deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate 7-day dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the school year, children in this arm will receive 7-day dosing of medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylphenidate 5-day dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the school year phase, these children will receive 5-day dosing with weekend holidays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
    <arm_group_label>Methylphenidate 5-day dosing</arm_group_label>
    <arm_group_label>Methylphenidate 7-day dosing</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of attention-deficit/hyperactivity disorder

          -  Full Scale IQ above 80

        Exclusion Criteria:

          -  Psychotropic medications for conditions other than ADHD

          -  Active medical or psychiatric conditions that could be worsened by stimulants

          -  Diagnosis of Autism or Asperger's Disorder

          -  Documented intolerance fo methylphenidate or failed trial of OROS MPH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Pelham, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James M Swanson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida International University Center for Children and Families</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ccf.fiu.edu</url>
    <description>Center for Children and Families General Information</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>July 29, 2019</results_first_submitted>
  <results_first_submitted_qc>August 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerance to stimulant medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02039908/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in 4 annual cohorts from 2013-2016. Participants could be referred by schools, physicians, or community advertisement; interested parents completed phone screens and a clinic intake to assess inclusionary and exclusionary criteria.</recruitment_details>
      <pre_assignment_details>Because all participants were required to be enrolled in a Summer Treatment Program, some participants withdrew after consenting because they were unable to make the time commitment to the 8-week summer program.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1-Summer; Medication First, Then Placebo</title>
          <description>In the first phase of the study, children participated in a crossover design of placebo and optimal-dose methylphenidate for 13 days in each condition. After a 9-day titration period, the Medication First group received their optimal dose of methylphenidate for 13 days, a 2-day medication/placebo probe, a 2-day washout, then placebo for 13 days and a 2-day medication/placebo probe.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1-Summer; Placebo First, Then Medication</title>
          <description>In the first phase of the study, children participated in a crossover design of placebo and optimal-dose methylphenidate for 13 days in each condition. After a 9-day titration period, the Placebo First group received placebo for 13 days, a 2-day medication/placebo probe, a 2-day washout, then optimal-dose medication for 13 days and a 2-day medication/placebo probe.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 School Year - 7-Day Dosing</title>
          <description>During the school year, all participants took their optimal dose determined in Phase 1 of the study for the entire school year. These partcipants received medication 7-days a week for the entire year.</description>
        </group>
        <group group_id="P4">
          <title>Phase 2 School Year; 5-Day Dosing</title>
          <description>During the school year, all participants took their optimal dose determined during Phase 1 for the entire school year. These participants received medication on school-days only with drug holidays over weekends.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1-Summer</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2-School Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1-Summer</title>
          <description>In the first phase of the study, all children participate in a crossover design of placebo and optimal-dose methylphenidate for 13 days in each condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Changes Required Per Protocol</title>
        <description>Monthly evaluations of medication efficacy will be used to determine whether dose adjustments are needed due to anticipated tolerance effects.</description>
        <time_frame>10 months</time_frame>
        <population>All participants who began Phase 2 were included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate 7-day Dosing</title>
            <description>During the school year, children in this arm will receive 7-day dosing of medication.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
          <group group_id="O2">
            <title>Methylphenidate 5-day Dosing</title>
            <description>During the school year phase, these children will receive 5-day dosing with weekend holidays.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Changes Required Per Protocol</title>
          <description>Monthly evaluations of medication efficacy will be used to determine whether dose adjustments are needed due to anticipated tolerance effects.</description>
          <population>All participants who began Phase 2 were included in analysis</population>
          <units>Number of Increases</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.16"/>
                    <measurement group_id="O2" value="1.61" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Increase</title>
        <description>The amount of time elapsed before a child requires a dose increase during the school year will be measured in months.</description>
        <time_frame>10 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate 7-day Dosing</title>
            <description>During the school year, children in this arm will receive 7-day dosing of medication.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
          <group group_id="O2">
            <title>Methylphenidate 5-day Dosing</title>
            <description>During the school year phase, these children will receive 5-day dosing with weekend holidays.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Increase</title>
          <description>The amount of time elapsed before a child requires a dose increase during the school year will be measured in months.</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.4"/>
                    <measurement group_id="O2" value="4.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medication Dose</title>
        <description>Dose of medication reported in mg/kg/day</description>
        <time_frame>End of Phase 2 School Year</time_frame>
        <population>Only participants who completed the entire school year are used in endpoint medication dosing calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate 7-day Dosing</title>
            <description>During the school year, children in this arm will receive 7-day dosing of medication.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
          <group group_id="O2">
            <title>Methylphenidate 5-day Dosing</title>
            <description>During the school year phase, these children will receive 5-day dosing with weekend holidays.
Methylphenidate: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medication Dose</title>
          <description>Dose of medication reported in mg/kg/day</description>
          <population>Only participants who completed the entire school year are used in endpoint medication dosing calculations.</population>
          <units>Mg/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.43"/>
                    <measurement group_id="O2" value="1.24" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During Phase 1, side effects ratings were collected from parents daily for the first 2 weeks of the summer and weekly for the final 6 weeks of the summer. During Phase 2, side-effects ratings were completed by parents monthly at medication dispensing visits.</time_frame>
      <desc>Parents completed the Pittsburgh Side Effects Rating Scale, rating each of the most common side effects of stimulant medication on a scale of None, Mild, Moderate, or Severe. Adverse events were counted if parents rated the side effect at the Moderate or Severe level on at least one occasion,</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1-Medication First</title>
          <description>In the first phase of the study, children participated in a crossover design of placebo and optimal-dose methylphenidate for 13 days in each condition. After a 9-day titration period, the Medication First group received methylphenidate for 13 days, a 2-day medication/placebo probe, a 2-day washout, then placebo for 13 days and a 2-day medication/placebo probe.</description>
        </group>
        <group group_id="E2">
          <title>Phase 1 - Placebo First</title>
          <description>In the first phase of the study, children participated in a crossover design of placebo and optimal-dose methylphenidate for 13 days in each condition. After a 9-day titration period, the Placebo First group received placebo for 13 days, a 2-day medication/placebo probe, a 2-day washout, then optimal-dose medication for 13 days and a 2-day medication/placebo probe.</description>
        </group>
        <group group_id="E3">
          <title>Phase 2 - 7-Day Dosing</title>
          <description>During the school year, all participants took their optimal dose determined in Phase 1 of the study for the entire school year. These participants received medication 7-days a week for the entire year</description>
        </group>
        <group group_id="E4">
          <title>Phase 2 - 5-Day Dosing</title>
          <description>During the school year, all participants took their optimal dose determined during Phase 1 for the entire school year. These participants received medication on school-days only with drug holidays over weekends.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized</sub_title>
                <description>Referred by parent for inpatient psychiatric treatment due to comorbid mental health issues.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Loss</sub_title>
                <description>Moderate or Severe Appetite Loss</description>
                <counts group_id="E1" events="252" subjects_affected="66" subjects_at_risk="129"/>
                <counts group_id="E2" events="265" subjects_affected="72" subjects_at_risk="138"/>
                <counts group_id="E3" events="131" subjects_affected="46" subjects_at_risk="121"/>
                <counts group_id="E4" events="143" subjects_affected="51" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Stomachache</sub_title>
                <description>Parent rating of moderate or severe stomach ache</description>
                <counts group_id="E1" events="51" subjects_affected="23" subjects_at_risk="129"/>
                <counts group_id="E2" events="55" subjects_affected="24" subjects_at_risk="138"/>
                <counts group_id="E3" events="29" subjects_affected="21" subjects_at_risk="121"/>
                <counts group_id="E4" events="25" subjects_affected="17" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="163" subjects_affected="52" subjects_at_risk="129"/>
                <counts group_id="E2" events="190" subjects_affected="56" subjects_at_risk="138"/>
                <counts group_id="E3" events="118" subjects_affected="46" subjects_at_risk="121"/>
                <counts group_id="E4" events="80" subjects_affected="34" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Motor Tics</sub_title>
                <description>Rating of moderate or severe motor tics</description>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="138"/>
                <counts group_id="E3" events="24" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Buccal-lingual movements</sub_title>
                <description>Parent rating of moderate or severe buccal-lingual movements</description>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Picking at skin, nailbiting</sub_title>
                <description>Parent rating of moderate or severe picking, nail-biting, etc.</description>
                <counts group_id="E1" events="83" subjects_affected="37" subjects_at_risk="129"/>
                <counts group_id="E2" events="90" subjects_affected="28" subjects_at_risk="138"/>
                <counts group_id="E3" events="73" subjects_affected="38" subjects_at_risk="121"/>
                <counts group_id="E4" events="91" subjects_affected="37" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Worried/Anxious</sub_title>
                <description>Parent rating of moderate or severe worry/anxiety</description>
                <counts group_id="E1" events="61" subjects_affected="27" subjects_at_risk="129"/>
                <counts group_id="E2" events="66" subjects_affected="30" subjects_at_risk="138"/>
                <counts group_id="E3" events="40" subjects_affected="25" subjects_at_risk="121"/>
                <counts group_id="E4" events="63" subjects_affected="34" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dull, tired, listless</sub_title>
                <description>Parent rating of moderate or severe dullness/tiredness/listlessness</description>
                <counts group_id="E1" events="56" subjects_affected="27" subjects_at_risk="129"/>
                <counts group_id="E2" events="61" subjects_affected="30" subjects_at_risk="138"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E4" events="32" subjects_affected="19" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Parent rating of moderate or severe headache</description>
                <counts group_id="E1" events="32" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E2" events="32" subjects_affected="19" subjects_at_risk="138"/>
                <counts group_id="E3" events="24" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E4" events="23" subjects_affected="14" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Parent rating of moderate or severe irritability</description>
                <counts group_id="E1" events="97" subjects_affected="42" subjects_at_risk="129"/>
                <counts group_id="E2" events="104" subjects_affected="46" subjects_at_risk="138"/>
                <counts group_id="E3" events="71" subjects_affected="38" subjects_at_risk="121"/>
                <counts group_id="E4" events="62" subjects_affected="36" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Tearful, depressed</sub_title>
                <description>Parent rating of moderate or severe tearfulness or sadness</description>
                <counts group_id="E1" events="49" subjects_affected="25" subjects_at_risk="129"/>
                <counts group_id="E2" events="53" subjects_affected="27" subjects_at_risk="138"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E4" events="31" subjects_affected="20" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Social Withdrawal</sub_title>
                <description>Parent rating of moderate or severe social withdrawal</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" events="28" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E4" events="16" subjects_affected="10" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William E. Pelham, Jr., Ph.D.</name_or_title>
      <organization>Florida International University</organization>
      <phone>305-348-0477</phone>
      <email>wpelham@fiu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

